Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced that Steve Buckanavage, Vice-President Global Marketing will be presenting for the company at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day in New York City on Tuesday, March 22, 2016 at TIME EST.

Steve Buckanavage: “We are excited to participate in the conference and provide an update on Celyad’s activities and key milestones in immune-oncology and cardiology for 2016.  We believe our unique immuno-oncology approach in engineered T-Cells, with our natural killer receptor program called NKR T-Cells, will generate interest on the part of peers and investors.“

This event is organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray. WATCH WEBCAST! 

Download press release(s)

Press release

305.96 Ko

Celyad notifies the European Medicines Agency (EMA) of its intention to file a Marketing A...

Next News

Celyad notifies the European Medicines Agency (EMA) of its intention to file a Marketing A...